Research Reports Coverage on Healthcare Stocks -- Aetna, Anthem, Humana, and BioScrip

Wednesday, September 21, 2016 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, September 21, 2016 /PRNewswire/ --

Pre-market, directs its attention to four Healthcare

companies, which are: Aetna Inc. (NYSE: AET), Anthem Inc. (NYSE: ANTM), Humana Inc. (NYSE: HUM), and BioScrip Inc. (NASDAQ: BIOS). According to the MSCI All Country Healthcare index, the global sector had outperformed the market by over 60% over the
past five years, yet had seen a deceleration during the last 12 months. These stocks research reports can be downloaded now by simply registering for free at:


At the close on Tuesday, shares in Hartford, Connecticut-based Aetna Inc. saw a slight decline of 0.17%, ending the day at $114.63. The stock recorded a trading volume of 959,900 shares. The Company's shares have advanced 6.75% on an YTD basis. The stock is trading above its 200-day moving average by 2.29%. Moreover, shares of Aetna, which operates as a health care benefits company in the US, have a Relative Strength Index (RSI) of 39.21.

On September 6th, 2016, Aetna and Piedmont Healthcare announced that the two organizations have signed a new contract. The agreement will give Aetna members continued in-network access to all Piedmont facilities and more than 1,400 Piedmont Clinic physicians through February 28th, 2019. Your complete research report on AET can be retrieved for free at:


Shares in Indianapolis, Indiana headquartered Anthem Inc. ended the day 0.44% lower at $125.76 and with a total trading volume of 1.77 million shares. The stock is trading below its 50-day moving average by 2.38%. Shares of the Company, which through its subsidiaries, operates as a health benefits company in the US, have an RSI of 43.59.

On September 13th, 2016, research firm Jefferies downgraded the Company's stock rating from 'Buy' to 'Hold'. The research firm also revised downwards its previous target price from $156 to $138. ANTM free report is just a click away at:


On Tuesday, shares in Louisville, Kentucky headquartered Humana Inc. finished 0.03% lower at $174.52 with a total trading volume of 394,133 shares. The stock is trading above its 50-day moving average by 0.64%. Shares of the Company, which together with its subsidiaries, operates as a health and well-being company, have an RSI of 39.72.

On September 14th, 2016, Oak Street Health and Humana teamed up to add four primary care practices to Humana's Medicare Advantage Plan networks in Indiana and Michigan. Humana is adding these new primary care practice locations to its network in an effort to improve access to care and quality of care while increasing patients' ability to manage their own care to improve their health and well-being. The new practices operated by Oak Street Health accept certain Medicare Advantage plans administered by Humana and do not accept Medicare Advantage plans administered by other carriers. Sign up for your complimentary research report on HUM at:


Denver, Colorado-based BioScrip Inc.'s shares recorded a trading volume of 1.24 million shares at the end of yesterday's session, which was higher than their three months average volume of 785,660 shares. The stock closed the day at $2.87, dropping 1.71%. The stock has advanced 1.77% in the last one month, 2.87% in the previous three months, and 64.00% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 7.35% and 24.72%, respectively. Additionally, shares of BioScrip, which provides home infusion services in the US, have an RSI at 61.26.

On September 9th, 2016, BioScrip announced that it has completed the acquisition of HS Infusion Holdings, Inc. As a combined company, BioScrip expects to generate over $1 billion in annual revenue for the fiscal year ending December 31st, 2017. The transaction is expected to be accretive to BioScrip's financial results and is estimated to generate $14-17 million of synergies in approximately 12-18 months following the closing. The additional financial contribution from Home Solutions, including anticipated synergies, is anticipated to strengthen BioScrip's balance sheet and leverage profile. Register for free on and download the latest research report on BIOS at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store